Central Council for Research in Homoeopathy, New Delhi, India.
Homeopathy. 2021 Aug;110(3):198-205. doi: 10.1055/s-0041-1725988. Epub 2021 Apr 14.
As at mid-October 2020, the coronavirus disease 2019 (COVID-19) pandemic has been continuing on the rise across the globe, including in India. Historically, homeopathy has been used in a number of epidemics/pandemics. The development of homeopathic medicines is approached uniquely through "drug provings" and clinical verification; these two intrinsic processes establish the background for the application of homeopathic medicines, regardless of nosological diagnosis. This article reflects research initiatives on COVID-19 in India and identifies studies listed in the Clinical Trial Registry-India database. We identified 29 studies being undertaken in different settings, including those in conventional medicine: 20 randomized controlled trials (RCTs) and 9 observational studies. Fifteen studies are aimed at prophylaxis and 14 are aimed at treatment. Amongst the treatment studies, 11 are focused on efficacy or comparative effectiveness. The findings might provide evidence for clinically repurposing some of homeopathy's medicines, an approach that is intrinsic to the therapy, enabling their use in COVID-19 as an adjuvant or stand-alone to help reduce costs and improve patient recovery.
截至 2020 年 10 月中旬，2019 年冠状病毒病（COVID-19）大流行在全球范围内持续上升，包括印度。从历史上看，顺势疗法在许多流行病/大流行中都有使用。顺势疗法药物的开发是通过“药物试验”和临床验证来进行的；这两个内在的过程为顺势疗法药物的应用奠定了基础，而不论疾病诊断如何。本文反映了印度在 COVID-19 方面的研究计划，并确定了在印度临床试验注册数据库中列出的研究。我们确定了在不同环境中进行的 29 项研究，包括常规医学中的研究：20 项随机对照试验（RCT）和 9 项观察性研究。15 项研究旨在预防，14 项研究旨在治疗。在治疗研究中，有 11 项侧重于疗效或比较疗效。这些发现可能为临床上重新利用顺势疗法的一些药物提供证据，这是该疗法的固有方法，使其能够在 COVID-19 中作为辅助治疗或单独使用，以帮助降低成本并提高患者的康复率。
